Pfizer acquires Metsera and its GLP-1 candidates in new $4.9bn obesity play0 SHARESPosted: 23 September 2025 | Dominic Tyer (European Pharmaceutical Review) |The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline. Pfizer has reinvigorated its ambition of competing with Novo Nordisk and Lilly in the lucrative obesity market, striking a $4.9 billion deal to acquire Metsera. Albert Bourla, Chairman and Chief Executive Officer at Pfizer, said: “Obesity is a large and growing space with over 200 health conditions associated with it. Chief among these is its phase II weekly and monthly injectable GLP-1 receptor agonist MET-097i, which is being evaluated as both a monotherapy and in combination with Metsera’s monthly, ultra-long acting GLP-1 receptor agonist MET-233i. Whit Bernard, Co-Founder and Chief Executive Officer of Metsera, said: “Since our founding in 2022, Metsera has worked tirelessly to reduce the physical, emotional, and economic burdens of obesity.